Free Trial
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Arbutus Biopharma logo
$3.66 -0.02 (-0.41%)
As of 12:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Key Stats

Today's Range
$3.66
$3.70
50-Day Range
$3.09
$3.67
52-Week Range
$2.70
$4.72
Volume
155,706 shs
Average Volume
867,984 shs
Market Capitalization
$700.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Arbutus Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ABUS MarketRank™: 

Arbutus Biopharma scored higher than 54% of companies evaluated by MarketBeat, and ranked 503rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arbutus Biopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Arbutus Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arbutus Biopharma is -12.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arbutus Biopharma is -12.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arbutus Biopharma has a P/B Ratio of 8.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arbutus Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.50% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently decreased by 4.84%, indicating that investor sentiment is improving.
  • Dividend Yield

    Arbutus Biopharma does not currently pay a dividend.

  • Dividend Growth

    Arbutus Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.50% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently decreased by 4.84%, indicating that investor sentiment is improving.
  • News Sentiment

    Arbutus Biopharma has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Arbutus Biopharma this week, compared to 3 articles on an average week.
  • Search Interest

    7 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arbutus Biopharma's insider trading history.
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABUS Stock News Headlines

Arbutus (ABUS) Q2 Revenue Surges 529%
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Arbutus Biopharma Corporation (ABUS) - Yahoo Finance
See More Headlines

ABUS Stock Analysis - Frequently Asked Questions

Arbutus Biopharma's stock was trading at $3.27 at the beginning of the year. Since then, ABUS shares have increased by 12.4% and is now trading at $3.6750.

Arbutus Biopharma Corporation (NASDAQ:ABUS) issued its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.03. The biopharmaceutical company had revenue of $10.74 million for the quarter, compared to analyst estimates of $2.21 million. Arbutus Biopharma had a negative net margin of 352.24% and a negative trailing twelve-month return on equity of 59.28%.

Arbutus Biopharma's top institutional shareholders include Two Seas Capital LP (5.45%), Geode Capital Management LLC (1.90%), BlackBarn Capital Partners LP (1.36%) and Adage Capital Partners GP L.L.C. (1.34%).
View institutional ownership trends
.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/06/2025
Today
8/29/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABUS
CIK
1447028
Employees
90
Year Founded
2005

Price Target and Rating

High Price Target
$7.00
Low Price Target
$5.00
Potential Upside/Downside
+49.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.92 million
Net Margins
-352.24%
Pretax Margin
-351.92%
Return on Equity
-59.28%
Return on Assets
-44.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.53
Quick Ratio
20.53

Sales & Book Value

Annual Sales
$6.17 million
Price / Sales
114.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.43 per share
Price / Book
8.53

Miscellaneous

Outstanding Shares
191,700,000
Free Float
152,784,000
Market Cap
$703.54 million
Optionable
Optionable
Beta
0.86

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ABUS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners